Antiangiogenic properties of beta-blockers
Year: 2018, volume 14 Issue: №4 Pages: 728-734
Heading: Dermatovenerology Article type: Original article
Authors: Dubensky VI.V, Dubensky V.V.
Organization: Tver State Medical University of the Ministry of Russia
Heading: Dermatovenerology Article type: Original article
Authors: Dubensky VI.V, Dubensky V.V.
Organization: Tver State Medical University of the Ministry of Russia
Summary:
Objective: determination of comparative antiangiogenic effectiveness and influence of beta-blockers on the level of a vascular endothelial factor of growth in an experiment. Material and Methods. For determination of antiangiogenic effect of beta-blockers, comparative studying of their influence on the level of a vascular endothelial factor of growth in an experiment on 72 nonlinear laboratory rats, by average weight 180±20 g which were conditionally divided into 6 groups is executed: 1st — control, 2nd — negative control (experimental ischemia (El), crossing of femoral vessels), 3rd — positive control (El with bevacizumab introduction), 4th — El with introduction of a timolol, 5th — El with introduction of a betaksolol, 6th — El with introduction of interferon alpha 2b. Results. The VEGF levels were: in 1st group 1.5±0.3 pg/ ml, in 2nd group 20,3±3,2 pg/ml, in 3rd group5,8±0,9 pg/ml, in 4th group 13,8±1,4 pg/ml, in 5th group 192,0±2,3 pg/ml, in 6th group 11,1 ±2,2 pg/ml. Results of microscopy and immunohistochemical research demonstrate lack of activation of processes of neoangiogenesis in 1 st group of animals. At animals of 2nd and 5th groups along with the expressed inflammatory processes the neoangiogenesis phenomena are established. Conclusion: Beta-blockers show the direct or mediated negative impact on synthesis of VEGF and oppression of neoangiogenesis. The activity of selective beta-blocker concerning neoangiogenesis suppression was lower in comparison by activity non-selective that allows to consider the timolol effective antiangiogenic remedy.
Bibliography:
1 Frieden IJ, etal. Infantile hemangiomas: current knowledge, future directions, proceedings of a research workshop on infantile hemangiomas. Pediatr Dermatol 2005; 22: 383-406
2 Dubensky VV, Dubensky VI.V. Etiopathogenesis and morphology of juvenile hemangiomas. Russian Journal of Skin and Venereal Diseases 2014; (4): 8-12
3 Bielenberg DR, et al. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, INF-beta. Int J Oncol 1999; 14: 401-8
4 Boye E, etal. Clonality and altered behaviour of endothelial cells from hemangiomas. J Clinlnvest 2001; 107: 745-52
5 Dubensky VV. New in the pathogenesis of juvenile hemangiomas. Modern problems of dermatovenerology, immunology, cosmetology 2013; (3): 26-31
6 ManciniAJ, etal. Proliferation and apoptosis within juvenile capillary hemangiomas. Am J Dermatopathol 1996; 18: 505-14
7 Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-51
8 Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131: 128-40
9 D'Angelo G, et al. cAMP-dependant protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997; 67: 353-66
10 Laccarino G, et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptors over expression: a novel role for the endothelial adrenergic system. Circ Res 2005; 97: 1182-9
11 Mironov AN, Bunatyan ND. Guidelines for pre-clinical trials of medicines. Moscow, 2012; 944 p.
12 Dubensky VV, Aun RYu. Efficacy and safety of topical p-blocker for the treatment of juvenile hemangiomas. Pharmateca: Dermatology/Allergology 2018; 32-9
13 Dubensky VV Influence of nonselective beta-blocker on chemotaxis and active migration of cells in vitro, in the aspect of treatment of juvenile hemangiomas. Immunopathology, Allergology, Infectology 2016; (4): 50-9.
| Attachment | Size |
|---|---|
| 2018_4-1_728-734.pdf | 1.33 MB |
Русский
English